Related Experiment Videos
Modern management of chronic venous insufficiency
1Department of Vascular Surgery, Birmingham Heartlands Hospital, Research Institute, Birmingham, United Kingdom. Andrew.Bradbury@heartsol.wmids.nhs.uk
Asian Journal of Surgery
|August 20, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial.
Health technology assessment (Winchester, England)·2026
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.
Health technology assessment (Winchester, England)·2024
Editor's Choice - Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 Trial: Analysis of the Timing and Causes of Death in Participants Randomised to an Infrapopliteal Vein Bypass or Best Endovascular Treatment First Revascularisation Strategy.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2024
Polycation chain length determines the in vivo mRNA delivery efficiency of block copolymer micelles.
Biomaterials science·2026
Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.
Small (Weinheim an der Bergstrasse, Germany)·2026
Mumio Potentiates Temozolomide by Inducing Apoptosis and Ferroptosis in Glioblastoma Cells.
Current pharmaceutical design·2026
Current Targeted Nanoparticle Therapy for Alzheimer's Disease: Current Advances and Future Prospects.
Current neurovascular research·2026
Clinical Presentation, Diagnosis, Treatment, and Outcome of Heart Disease in Becker Muscular Dystrophy.
Anatolian journal of cardiology·2026
Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.
Journal of clinical pharmacology·2026